Evaluate (Norstella)
Overview
Pharma commercial intelligence provider whose EvaluatePharma consensus sales forecasts and market sizing are an industry standard for asset valuation and portfolio strategy. Offers the Omnium predictive risk-return platform and AI analyst tools grounded in its proprietary forecast data.
Notable
Merged with MMIT in 2021 and became a founding brand of Norstella (2022) alongside Panalgo, The Dedham Group, and Citeline; contributes forecast intelligence to the NorstellaLinQ integrated data asset.
Key services
- consensus sales forecasts (EvaluatePharma)
- market sizing and competitive intelligence
- risk-adjusted asset valuation (Omnium)
- commercial landscape analytics
- Ask Ella AI analyst
Subcategories
Verified Reviews
No verified reviews yet — are you a customer of Evaluate (Norstella)? Share your experience in a short, confidential interview.
Share your experience